Scientific Organizers:
Chris Boshoff, Pfizer Inc.
Lieping Chen, Yale University, USA
Lisa Coussens, Oregon Health & Science University, USA

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to the generous support from an anonymous donor

By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This meeting helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.

Session Topics:
• Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
• Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations
• Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens
• Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
• Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
• Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
• Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
• Vaccines, Oncolytic Viruses and Cellular Therapies: Towards Combinations
• CTLA-4: Novel Molecules and Approaches to Combinations
• HFrEF: Genetics and Epigenetics

Scholarship Application & Discounted Abstract Deadline: November 21, 2017
Abstract Deadline: December 19, 2017
Discounted Registration Deadline: January 16, 2018

Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Submitting an abstract is an excellent opportunity to gain exposure for your work. Abstracts submitted by the abstract deadline will also be considered for short talks on the program.

Upper image of killer T cells surrounding a cancer cell courtesy of Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths, National Institutes of Health

Meeting Hashtag: #KScancerimm
www.keystonesymposia.org/18C5
FRIDAY, MARCH 23
Arrival and Registration

SATURDAY, MARCH 24
Welcome and Keynote Session
*Chris H. Boshoff, Pfizer Inc., USA
*Lieping Chen, Yale University, USA
*Lisa M. Coussens, Oregon Health & Science University, USA
Jedd D. Wolchok, Sloan Kettering Cancer Center, USA
Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapy Converts Pancreatic Cancers into an Immunologically Inert Disease

Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responsive
*Judith A. Varner, University of California, San Diego, USA
Lieping Chen, Yale University, USA
Design of Combination Therapy-Based Adaptive Resistance Mechanisms in Tumor Microenvironment
Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy

Simone A. Minnie, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Stem Cell Transplantation Establishes T Cell-Dependent Myeloma Immune-Equilibrium that Can Be Enhanced with Immunotherapy

Hyejin Choi, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Optimizing Targeted Therapy and Immune Checkpoint Blockade Therapy in Kras Mutant Lung Cancer

Workshop: Novel and Sequencing Approaches
*Chris H. Boshoff, Pfizer Inc., USA
Bradley N. Mills, University of Rochester, USA
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer

Adrienne Rothschilds, Massachusetts Institute of Technology, USA
Order of Administration of Combination Cytokine Therapies Can Decouple Toxicity from Efficacy in Syngeneic Mouse Tumor Models

Alvaro de Mingo Pulido, Moffitt Cancer Center, USA
TIM-3 Regulates cDC1 Function and Response to Chemotherapy in Breast Cancer

Jiemiao Hu, University of Texas MD Anderson Cancer Center, USA
Combination Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors

Christopher D. Zahm, University of Wisconsin-Madison, USA
TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Mediated Regulation

Hayley S. Ma, Kineta Inc., USA
Combination CD40 Agonist and PD-1 Antagonist Antibody Therapy Enhances Vaccine-Induced T Cell Responses in Non-Immunogenic Cancers

Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens
*Jane L. Grogan, Genentech, Inc., USA
Ronald Herbst, MedImmune, USA
Combination Therapy for Cancer: Beyond Checkpoint Inhibition

Andy Minn, University of Pennsylvania, USA
Interferon-Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy

Sonia Harnois, Bristol-Myers Squibb, Canada
Short Talk: Relatlimab, An Anti-LAG-3, in Combination with Nivolumab in Melanoma Patients Who Progressed on Anti-PD-1/PD-L1

Karina Knudson, NCI, National Institutes of Health, USA
Short Talk: An IL-15 Superagonist ALT803 in Combination with an Anti-PD-L1

Poster Session 1

SUNDAY, MARCH 25
Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
*Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions between Myeloid and Lymphoid Cells Regulate Response to Therapy in Solid Tumors

Judith A. Varner, University of California, San Diego, USA
Targeting Tissue-Resident Macrophages and Their Progenitors to Suppress Cancer Progression

Chris H. Boshoff, Pfizer Inc., USA
Combining Immune Checkpoint Inhibitors with Targeted Therapies

Jane L. Grogan, Genentech, Inc., USA
Epigenetic Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain

Sabrin Mishel, University of Toronto, Canada
Short Talk: Proximal Signaling through the Innate Immune Inhibitory Receptor Signal Regulatory Protein alpha (SIRPa) in Primary Macrophages

Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
*Lisa M. Coussens, Oregon Health & Science University, USA
Sergio A. Quezada, University College London, UK
Using Preclinical Models and Clinical Samples to Inform Mechanisms and Rational Combinations

Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity

Bernard A. Fox, Earle A Chiles Research Institute, USA
Sequencing Checkpoint Therapies

* Session Chair † Invited but not yet accepted  Program current as of June 25, 2019. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit www.keystonesymposia.org/18C5.
Ralf Huss, Definiens AG, Germany
Short Talk: Multiplex Immuno-Oncology Panel for Standardized Cancer Profiling of the Immune Status Based on the Spatial and Functional Characterization in the Tumor Microenvironment

Poster Session 2

MONDAY, MARCH 26

Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
* Sergio A. Quezada, University College London, UK
Peter S. Hammerman, Novartis Institutes for BioMedical Research, USA
Adaptive Resistance to Immune Checkpoint Blockade
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Molecular and Epigenetic Programs Defining Tumor-Specific T Cell Dysfunction
Gregory Lawrence Beatty, University of Pennsylvania, USA
Strategies for Incorporating CD40 Agonists in Cancer Therapy
Yong-Jun Liu, Sanofi, USA
Next Generation of Immunotherapy: Targeting Anti-PD1 Resistance
Ramsay Khader, Barts Cancer Institute, UK
Pegylated Arginine Deiminase and PD-1/PD-L1 Blockade in the Treatment of ASS1-Deficient Cancers
Overcoming T Cell Exclusion and an Immune-Privileged Environment with Combination Approaches
* Lieping Chen, Yale University, USA
Douglass T. Fearon, Cold Spring Harbor Laboratory, USA
CXCR4 Mediates Immune Privilege in T Cell-Excluded Tumors
Daniela F. Quail, McGill University, Canada
Cellular Mechanisms of Combination Checkpoint Blockade

CTLA-4: Novel Molecules and Approaches to Combinations
* Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Cellular Mechanisms of Combination Checkpoint Blockade
Mario Sznol, Yale School of Medicine, USA
Lessons Learned from Anti-CTLA-4 and Anti-PD-1 Combination
Alan J. Korman, Bristol-Myers Squibb, USA
Next-Generation Anti-CTLA-4 Antibodies

Meeting Wrap-Up: Outcomes and Future Directions
* Chris H. Boshoff, Pfizer Inc., USA
* Lieping Chen, Yale University, USA
* Lisa M. Coussens, Oregon Health & Science University, USA

WEDNESDAY, MARCH 28

Departure